

PRESENTATION OF APAS® AT ASM MICROBE

Largest life science society meeting in North America held in Atlanta, USA, 7 – 11 June 2018

Adelaide, Australia, 7 June 2018: LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in medical technology automation using artificial intelligence is pleased to announce that joint venture partner Clever Culture Systems (**CCS**) will be presenting a Poster Presentation at the American Society for Microbiology Microbe (**ASM Microbe**).

ASM Microbe, will take place in Atlanta, United States of America, from 7 – 11 June 2018. The American Society for Microbiology is the largest single life science society comprising over 50,000 scientists and health professionals. The ASM Microbe showcases the best microbial sciences in the world and is the largest meeting of microbiologists in North America.

The Poster utilises the data from St Vincent’s Hospital’s evaluation of the APAS® Independence, completed in late 2017. It outlines the analytical technique and approach used providing guidance to laboratories in performing statistical analysis of discrepant resolution in an unbiased manner. The Poster will be released publicly on Saturday 9 June 2018 and is titled:

Discrepant Result Analysis for Emerging Technologies in Microbiology.

The Poster will be available on the Company’s website following the presentation at ASM Microbe.

A team of senior commercial and technical staff from LBT, lead by CEO Brent Barnes, together with Peter Bradley, General Manager of LBT’s joint venture, CCS, will also be attending the conference and hosting an industry booth to showcase the APAS® Independence instrument. This will provide CCS with the opportunity to demonstrate the capability of the APAS® Independence to U.S. clinicians, potential customers, as well as distributors and partners attending the conference.

– ENDS –

About LBT Innovations

LBT Innovations Limited (**LBT**) improves patient outcomes by making healthcare more efficient. Based in Adelaide, South Australia, the Company has two world class-leading products in microbiology automation: MicroStreak®, which provides automated culture plate streaking and Automated Plate Assessment System (**APAS**®). Based on LBT’s intelligent imaging and interpretative software, US FDA-cleared APAS® automates imaging, analysis and interpretation of culture plates following incubation. LBT has entered into a joint venture Clever Culture Systems AG (**CCS**) with Hettich Holding Beteiligungs- und Verwaltungs-GmbH to commercialise APAS® products. LBT’s third product WoundVue® is in early development; this is a proposed automated solution to assist in the management of chronic wounds.

CONTACTS

LBT Innovations	Investor Enquiries	Media Relations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com	David Allen / John Granger Hawkesbury Partners Tel: +61 2 9103 9494 E: dallen@hawkesburypartners.com	Sarah Kemter Monsoon Communications Tel: +61 3 9620 3333 E: sarahk@monsoon.com.au